Halogen Patents (Class 424/1.85)
-
Patent number: 7172749Abstract: Radiolabeled epidermal growth factor receptor tyrosine kinase (EGFR-TK) irreversible inhibitors and their use as biomarkers for medicinal radioimaging such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) and as radiopharmaceuticals for radiotherapy are disclosed.Type: GrantFiled: September 11, 2003Date of Patent: February 6, 2007Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem, Hadasit Medical Research Services and Development Ltd.Inventors: Alexander Levitzki, Eyal Mishani, Giuseppina Ortu, Iris Ben-David, Yulia Rozen
-
Patent number: 7169377Abstract: One embodiment of the invention is a composition that comprises a radioactive [18F], [123I], [125I], or [131I]-N-radiohaloaryl-alkylcarboxamide molecule. The composition binds to the transient receptor potential-M8 (TRP-M8) receptor of cells. The TRP-M8 receptor is selectively expressed in sensory neurons and in malignant tissues such as prostate cancer cells. The [18F], [123I], [125I], or [131I]-N-radiohaloaryl-alkylcarboxamide ligand may be used for radioreceptor binding studies, for diagnostic studies, and for radiotherapy of cancerous tissues. Affinity of the [125I] or [131I]-N-radiohaloaryl-alkylcarboxamide ligand for the TRP-M8 receptor confers selectivity and specificity in delivering lethal radiation to the diseased cells.Type: GrantFiled: October 15, 2003Date of Patent: January 30, 2007Inventor: Edward T. Wei
-
Patent number: 7118731Abstract: An agent which comprises, as an active ingredient, a radiolabeled compound as represented by the following formula or a pharmaceutically acceptable salt thereof: wherein R1 denotes hydrogen, or a linear- or branched-chain alkyl group having 1–8 carbon atoms, R2 denotes hydrogen, hydroxyl or a halogen substituent, R3 denotes hydrogen or fluorine substituent, R4 denotes oxygen, sulfur, or a methylene substituent, and R5 denotes a radioactive halogen substituent. The agent is stable in vivo, and either stays in cells or is incorporated in DNA, thus serving for diagnosis of tissue proliferation activity or treatment of proliferative disease.Type: GrantFiled: November 16, 2004Date of Patent: October 10, 2006Assignee: Nihon Medi-Physics Co., Ltd.Inventors: Jun Toyohara, Akio Hayashi
-
Patent number: 7115249Abstract: The invention relates to compounds of formula (I); wherein R1 and R2 independently selected from C1-6 alkyl; P1, P2, P3, and P4 are each independently hydrogen or a protecting group; and their use in the preparation of 18F-labelled 6-L-fluorodopaType: GrantFiled: June 18, 2002Date of Patent: October 3, 2006Assignees: GE Healthcare Ltd., Hammersmith Imanet Ltd.Inventors: Sajinder Kaur Luthra, Frank Brady, Harry John Wadsworth
-
Patent number: 7112318Abstract: The invention provides a series of lipophilic phosphonium cations (PhCs) labeled with 18F for non-invasive assessment of ??m, lipophilic ammonium cation analogs of the PhCs, and methods of using same for imaging and detection of mitochondrial-related pathologies in patients using PET or SPECT.Type: GrantFiled: February 6, 2003Date of Patent: September 26, 2006Assignee: The Johns Hopkins UniversityInventors: Igal Madar, Hayden T. Ravert, Robert Francis Dannals, Ursula A. Scheffel, James J. Frost
-
Patent number: 7060251Abstract: The invention provides imaging agents comprising a label in association with a plaque specific targeting molecule. Methods for using the imaging agents to diagnose or monitor plaque formation and growth and kits containing the cardiovascular agents or components suitable for production of the imaging agents are also provided.Type: GrantFiled: September 8, 1998Date of Patent: June 13, 2006Assignee: The General Hospital CorporationInventors: David R. Elmaleh, Alan J. Fischman, John W. Babich
-
Patent number: 7045115Abstract: An agent which comprises, as an active ingredient, a radiolabeled compound as represented by the following formula or a pharmaceutically acceptable salt thereof: wherein R1 denotes hydrogen, or a linear- or branched-chain alkyl group having 1–8 carbon atoms, R2 denotes hydrogen, hydroxyl or a halogen substituent, R3 denotes hydrogen or fluorine substituent, R4 denotes oxygen, sulfur, or a methylene substituent, and R5 denotes a radioactive halogen substituent. The agent is stable in vivo, and either stays in cells or is incorporated in DNA, thus serving for diagnosis of tissue proliferation activity or treatment of proliferative disease.Type: GrantFiled: January 22, 2002Date of Patent: May 16, 2006Assignee: Nihon Medi-Physics Co., Ltd.Inventors: Jun Toyohara, Akio Hayashi
-
Patent number: 7018610Abstract: One aspect of the present invention relates to novel compounds that can be used to prepare radiolabeled compounds in an effective manner. A second aspect of the present invention relates to a method of synthesizing radiolabeled compounds.Type: GrantFiled: March 4, 2002Date of Patent: March 28, 2006Assignee: University of Western OntarioInventors: Duncan H. Hunter, Mustafa Janabi
-
Patent number: 7011813Abstract: Tropane derivatives having a high binding affinity and selectivity for dopamine transporters bear, on the tropane backbone either a carboxylic ester or isoxazole moiety, as well as a substituted phenyl moiety. The compounds have utility both as pharmaceutical and as imaging agents, when one or more atoms are radioactive.Type: GrantFiled: May 28, 2002Date of Patent: March 14, 2006Assignee: Research Triangle InstituteInventors: Michael J. Kuhar, Frank Ivy Carroll, John W. Boja, Anita H. Lewin, Philip Abraham
-
Patent number: 6991776Abstract: New intracorporeal radiodense medicaments and certain medical uses and methods for use of such high energy phototherapeutic medicaments for treatment of human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. The halogenated xanthenes constitute a family of potent radiosensitizers that become photoactivated upon irradiation of the treatment site with ionizing radiation.Type: GrantFiled: December 30, 2002Date of Patent: January 31, 2006Assignee: Xantech Pharmaceuticals, Inc.Inventors: H. Craig Dees, Timothy C. Scott, Eric A. Wachter, Walter G. Fisher, John Smolik
-
Patent number: 6974567Abstract: Detectably labeled macrophage scavenger receptor antagonists useful for the diagnosis and monitoring of various cardiovascular diseases including but not limited to atherosclerosis, vulnerable plaque, coronary artery disease, renal disease, thrombosis, transient ischemia due to clotting, stroke, myocardial infarction, organ transplant, organ failure and hypercholesterolemia.Type: GrantFiled: August 14, 2003Date of Patent: December 13, 2005Assignee: Bristol-Myers Squibb Pharma CompanyInventors: David Scott Edwards, Shuang Liu
-
Patent number: 6951640Abstract: The present invention covers halogenated derivatives of boronated phorphyrins containing multiple carborane cages having the formula which selectively accumulate in neoplastic tissue within the irradiation volume and thus can be used in cancer therapies including, but not limited to, boron neutron-capture therapy and photodynamic therapy. The present invention also covers methods for using these halogenated derivatives of boronated porphyrins in tumor imaging and cancer treatment.Type: GrantFiled: February 27, 2003Date of Patent: October 4, 2005Assignee: Brookhaven Science Associates, LLCInventors: Michiko Miura, Daniel N. Slatkin
-
Patent number: 6946116Abstract: This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form-amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.Type: GrantFiled: December 19, 2003Date of Patent: September 20, 2005Assignee: The Trustees of the University of PennsylvaniaInventors: Hank F. Kung, Mei-Ping Kung, Zhi-Ping Zhuang
-
Patent number: 6939966Abstract: The present invention is directed to radiolabeled neuropeptide Y Y5 receptor antagonists which are useful for the labeling and diagnostic imaging of neuropeptide Y Y5 receptors in mammals.Type: GrantFiled: July 19, 2002Date of Patent: September 6, 2005Assignees: Merck & Co., Inc., Banyu Pharmaceutical Co., Ltd.Inventors: H. Donald Burns, Raymond E. Gibson, Terence G. Hamill, Takehiro Fukami
-
Patent number: 6911219Abstract: This relates to partially acetalized polyvinyl alcohol embolization particles suitable for implanting in the human body, to compositions containing those particles, and to methods of making and using them.Type: GrantFiled: April 25, 2002Date of Patent: June 28, 2005Assignee: Surgica CorporationInventors: Louis R. Matson, Donald K. Brandom
-
Patent number: 6878363Abstract: A method of using radiolabelled and/or radiopharmaceutical small molecule inhibitors of beta-amyloid peptide production for the diagnosis of neurological and other disorders involving APP processing and beta-amyloid production. Radiolabelled small molecule inhibitors identified by the methods of the present invention would be useful in the diagnosis of neurological disorders, such as Alzheimer's disease, which involve elevated levels of A? peptides.Type: GrantFiled: May 17, 2001Date of Patent: April 12, 2005Assignee: Bristol-Myers Squibb Pharma CompanyInventors: Robert Zaczek, Richard E. Olson, Dietmar A. Seiffert, Lorin A. Thompson
-
Patent number: 6872381Abstract: This invention is directed to the use of radiopharmaceuticals in diagnosing Alzheimer's disease. In particular the radiopharmaceuticals of the invention are able to pass through the blood-brain barrier and bind to the CCR1 receptor present in brain tissue of patients having Alzheimer's disease.Type: GrantFiled: July 25, 2003Date of Patent: March 29, 2005Assignee: Schering AGInventors: Christoph-Stephan Hilger, Bernd Johannsen, Joerg Steinbach, Peter Maeding, Meredith Halks-Miller, Richard Horuk, Harald Dinter, Raju Mohan, Joseph E. Hesselgesser
-
Patent number: 6861044Abstract: The present invention concerns the use of a radioiodinated phenolic compound of the formula wherein: m and n are independently 0, 1, 2 or 3, X is a group that is negatively or positively charged at physiological pH, R, R1, R2 and R3 are independently hydrogen, C1-C4 alkyl, or a carboxyl group, and I* is 123I, 131I or 125I, and its pharmaceutically-acceptable salts. The compound is formulated and used in vivo in an animal in brachytherapy in an implantable catheter. In addition, due to the rapid renal clearance of these compounds, they may be used to study renal function. A process to prepare these compounds is also disclosed.Type: GrantFiled: December 18, 2001Date of Patent: March 1, 2005Assignee: The Dow Chemical CompanyInventors: Jaime Simon, R. Keith Frank, Alan D. Strickland
-
Patent number: 6843979Abstract: A series of compounds in the 4-fluoroalkyl-3-halophenyl nortropanes and 4-haloethenylphenyl tropane families are described as diagnostic and therapeutic agents for diseases associated with serotonin transporter dysfunction. These compounds bind to serotonin transporter protein with high affinity and selectivity. The invention provides methods of synthesis which incorporate radioisotopic halogens at a last step which permit high radiochemical yield and maximum usable product life. The radiolabeled compounds of the invention are useful as imaging agents for visualizing the location and density of serotonin transporter by PET and SPECT imaging.Type: GrantFiled: October 9, 2001Date of Patent: January 18, 2005Assignee: Emory UniversityInventors: Mark M. Goodman, Laurent Martarello
-
Patent number: 6824760Abstract: Compounds of formula (I) and (II): wherein groups R1, R2, RE, PG1 and PG2 have the definitions provided in the specification, methods of manufacture and methods of use.Type: GrantFiled: June 4, 2001Date of Patent: November 30, 2004Assignee: The University of Texas SystemInventors: Akira Tanaka, Tomio Inoue, Katsumi Tomiyoshi, David J. Yang, E. Edmund Kim
-
Publication number: 20040197844Abstract: Use of pregnancy-associated plasma protein-A as a marker for inflammatory conditions, and in particular, for acute coronary syndromes is described.Type: ApplicationFiled: January 29, 2004Publication date: October 7, 2004Applicant: Mayo Foundation for Medical Education and Research, a Minnesota CorporationInventors: Cheryl A. Conover, Antonio Bayes-Genis, David R. Holmes, Robert S. Schwartz
-
Patent number: 6749830Abstract: The present invention relates to a new method for radiolabeling chemical compounds. The new method attains the goals of simplicity, high radiochemical yields, speed, versatility, and automation. An HPLC injection loop on an HPLC injection valve is loaded with a solution of precursor and the radiolabeling reagent is passed through the loop. The contents of the loop are then quantitatively injected onto the HPLC column for purification. Radiochemical yields are equal to or superior to conventional solution methods in all cases, even though no heat need be applied. Since no vials, transfer lines, cooling, heating, or sealing valves are required, no transfer losses occur, yields are high, and clean-up is minimal. This “loop method” is ideal for the preparation of radiolabeled compounds, in particular those prepared from [11C]-iodomethane.Type: GrantFiled: January 31, 2002Date of Patent: June 15, 2004Assignee: Centre for Addiction and Mental HealthInventors: Alan Alexander Wilson, Armando Francisco Garcia, Li Jin, Sylvain Joseph Houle
-
Patent number: 6749832Abstract: Compounds of formula (I) where: X1 is OH or SH or NH2 or —L-Z; X2 and X3 are the same or different and each is H, C1-4 alkyl, benzyl a protecting group or —L-Z, X4 is H or C1-4 alkyl, L is a linker comprising a chain of 0-10 atoms, Z is a group comprising a detectable moiety which comprise at least one detectable moiety are useful in the diagnosis and prognosis and radiotherapy of metastatic bone disease.Type: GrantFiled: September 16, 2002Date of Patent: June 15, 2004Assignee: Amersham PLCInventors: Susan Champion, Richard Pither
-
Patent number: 6740304Abstract: The present invention relates to a receptor binding conjugate which consists of an antibody, a radionuclide and folate or a folate derivative, wherein or not the conjugate possesses dual binding ability. The present invention also relates to a method and a kit to prepare, as well as a method to use, such conjugates. Furthermore, the use of a conjugate according to the present invention to prepare a pharmaceutical solution is disclosed.Type: GrantFiled: December 5, 2000Date of Patent: May 25, 2004Assignee: Anticancer Therapeutic Inventions ASInventors: Roy H. Larsen, Gjermund Henriksen
-
Patent number: 6699675Abstract: Use of pregnancy-associated plasma protein-A as a marker for inflammatory conditions, and in particular, for acute coronary syndromes is described.Type: GrantFiled: July 31, 2002Date of Patent: March 2, 2004Assignee: Mayo Foundation for Medical Education and ResearchInventors: David R. Holmes, Robert S. Schwartz
-
Patent number: 6696089Abstract: The present invention relates to nanogel networks having at least one cross-linked polyionic polymer fragment and at least one nonionic water-soluble polymer fragment, and compositions thereof, having at least one suitable biological agent.Type: GrantFiled: December 21, 2001Date of Patent: February 24, 2004Assignee: Board of Regents of the University of NebraskaInventors: Alexander V. Kabanov, Sergey V. Vinogradov
-
Patent number: 6693091Abstract: A compound having the structure: wherein R1 is H, OH, a photoactivatable moiety, a fluorescent moiety, or a radioactive moiety; wherein R2 is H, OH, a photoactivatable moiety, a fluorescent moiety, or a radioactive moiety; wherein R3 is H or OH; wherein R4 is H, OH, a photoactivatable moiety, a fluorescent moiety, or a radioactive moiety; and wherein at least one of R1, R2, R3, or R4 is a photoactivatable moiety, a fluorescent moiety, or a radioactive moiety. Optically pure enantiomers and salts of the compound are also described. Also, the synthesis of the compound, and uses of the compound, such as in a method for detecting the localization of, or identifying, receptors, enzymes or other targets, whether in a cell or in a subject.Type: GrantFiled: March 29, 2002Date of Patent: February 17, 2004Assignee: The Trustees of Columbia University in the City of New YorkInventors: Kristian Stromgaard, Makiko Suehiro, Koji Nakanishi
-
Patent number: 6686458Abstract: The present invention features biarsenical molecules. Target sequences that specifically react with the biarsenical molecules are also included. The present invention also features kits that include biarsenical molecules and target sequences. Tetraarsenical molecules are also featured in the invention.Type: GrantFiled: April 19, 2002Date of Patent: February 3, 2004Assignee: The Regents of the University of CaliforniaInventors: Roger Y. Tsien, B. Albert Griffin
-
Patent number: 6676925Abstract: Detectably-labeled compounds of formula (I) wherein A,B,C,D,E,F,R,X,Y and Z have any of the meanings given in the specification, and their pharmaceutically acceptable salts, are useful in competitive assays to assay for the presence of 2 receptors. Also disclosed are pharmaceutical compositions containing such a compound of formula (I), methods for their use and intermediates useful for preparing such compounds of formula (I).Type: GrantFiled: March 20, 2000Date of Patent: January 13, 2004Assignee: Wake Forest UniversityInventors: Robert H. Mach, Kenneth T. Wheeler, Biao Yang, Steven R. Childers
-
Patent number: 6660530Abstract: A method for labeling &bgr;-amyloid plaques and neurofibrillary tangles in vivo and in vitro, comprises contacting a compound of formula (I): with mammalian tissue.Type: GrantFiled: June 26, 2001Date of Patent: December 9, 2003Assignee: The Regents of the University of CaliforniaInventors: Jorge R. Barrio, Andrej Petric, Nagichettiar Satyamurthy, Gary W. Small, Gregory M. Cole, Sung-Cheng Huang
-
Patent number: 6632418Abstract: The present invention relates to novel radioligands and test methods using those radioligands in screening compounds.Type: GrantFiled: July 30, 2002Date of Patent: October 14, 2003Assignee: Abbott LaboratoriesInventors: Robert J. Altenbach, Gary A. Rotert, William A. Carroll, Murali Gopalakrishnan, Eduardo Jose Vicente Molinari, Rachel A. Davis-Taber, Victoria Eleanor Sarah Scott
-
Patent number: 6617459Abstract: The present invention relates to 8-azabicyclo[3.2.1]oct-2-ene derivatives in their labelled form. Furthermore, the present invention relates to the use of said derivatives in their labelled or unlabelled form in diagnostic methods, in particular for in vivo receptor imaging (neuroimaging).Type: GrantFiled: May 15, 2001Date of Patent: September 9, 2003Assignee: NeuroSearch A/SInventors: Dan Peters, Jørgen Scheel-Krüger, Elsebet Østergaard Nielsen
-
Patent number: 6589504Abstract: The invention provides methods for diagnosing and treating amyloid-related conditions and compounds useful for the same. The invention provides for detecting, imaging, monitoring, diagnosing, and treating conditions characterized by the binding or aggregation of amyloid fibrils. More particularly, the invention relates to using quinolinehydrazone compounds for diagnosing and treating amyloidotic conditions and also as an antioxidant.Type: GrantFiled: September 22, 2000Date of Patent: July 8, 2003Assignee: Pharmacia & Upjohn CompanyInventors: Thomas J. Raub, Geri A. Sawada, Steven P. Tanis, Gregory J. Fici, Allen Edwin Buhl, Donald Bainbridge Carter, Tiziano Bandiera, Jacqueline Lansen, Cesare Pellerano, Luisa Savini
-
Patent number: 6572823Abstract: An apparatus and method are provided for handling a solution. The apparatus comprises a housing and a vial assembly positioned within an enclosure of the housing. The vial assembly maintains at least one vial within the enclosure of the housing. A valve manifold extends within the enclosure of the housing for connection to the vial. A rotation mechanism, also extending within the enclosure of the housing, is operatively connected to the vial assembly for rotating the vial assembly.Type: GrantFiled: December 8, 1999Date of Patent: June 3, 2003Assignee: Bristol-Myers Squibb Pharma CompanyInventors: John J. Donahue, Joseph Haepers
-
Patent number: 6565829Abstract: The invention provides derivatives of 5-arylsulfonyl indole and 5-arylsulfonyl indoline compounds which may be in the form of pharmaceutical acceptable salts or compositions that are useful in treating central nervous system diseases such as anxiety and depression. The invention also includes intermediates and processes to make the compounds, isotopically-labeled forms of the compounds and the use of the isotopically labeled forms of the compounds to perform nuclear magnetic resonance imaging and positron emission tomography.Type: GrantFiled: August 1, 2002Date of Patent: May 20, 2003Assignee: Pharmacia & Upjohn CompanyInventor: Jian-Min Fu
-
Patent number: 6562319Abstract: Radiolabeled epidermal growth factor receptor tyrosine kinase (EGFR-TK) irreversible inhibitors and their use as biomarkers for medicinal radioimaging such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) and as radiopharmaceuticals for radiotherapy are disclosed.Type: GrantFiled: March 12, 2001Date of Patent: May 13, 2003Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem, Hadasit Medical Research Services and Development Ltd.Inventors: Eyal Mishani, Iris Ben-David, Yulia Rozen, Gluseppina Ortu, Alexander Levitzki
-
Patent number: 6537522Abstract: Iodinated neuroprobes for mapping monoamine reuptake sites in the brain, and particularly iodinated neuroprobes that can also serve as radiotracers for use in single-photon emission computed tomography (SPECT) and positron emission tomography (PET) for imaging of such reuptake sites, are disclosed. Precursors of radiolabeled iodinated neuroprobes, both with and without a radiotracer atom, and kits for preparing the radiolabeled iodinated neuroprobes are also disclosed.Type: GrantFiled: May 12, 1998Date of Patent: March 25, 2003Assignee: Amersham PLCInventors: John L. Neumeyer, Richard A. Milius, Robert B. Innis, Gilles Tamagnan, Shaoyin Wang
-
Patent number: 6524552Abstract: The invention provides a composition of matter of the formula (I): V—L—R where V is an organic group having binding affinity for an angiotensin II receptor site, L is a linker moiety or a bond, and R is a moiety detectable in in vivo imaging of a human or animal body, with the provisos that where V is angiotensin or a peptidic angiotensin derivative or analog then V—L—R is other than a non-metal radionuclide substituted peptide (e.g. 125I substituted angiotensin II) and L—V is other than simply a peptide with a chelating agent amide bonded to a side chain thereof. This composition of matter may be used to image cardiovascular diseases and disorders.Type: GrantFiled: February 20, 2001Date of Patent: February 25, 2003Inventors: Jo Klaveness, Anne Naevestad, Alan Cuthbertson
-
Patent number: 6517811Abstract: The present invention relates to a class of compounds having affinity for certain cancer cells, e.g. lung carcinomas, colon carcinomas, renal carcinomas, prostate carcinomas, breast carcinomas, malignant melanomas, gliomas, neuroblastomas and pheochromocytomas. The compounds of the present invention can also bind with high specificity to cell surface sigma receptors and can therefore be used for diagnostic imaging of any tissue having an abundance of cells with sigma receptors. The present invention provides such compounds as agents for diagnostic imaging and for detecting and treating tumors containing the cancer cells described above.Type: GrantFiled: January 5, 2001Date of Patent: February 11, 2003Assignee: Research Corporation Technologies, Inc.Inventors: Christy S. John, Jesse Baumgold, John G. McAfee, Terry Moody, Wayne Bowen
-
Patent number: 6509003Abstract: The present invention relates to N-alkylpiperidine derivatives represented by general formula (1) or (2); wherein R1 represents optionally fluorinated lower alkyl; R2 represents lower alkyl; and R3 represents alkenyl substituted at the 1-position with hydroxy, lower alkoxy, lower alkoxyalkyloxy, lower alkoxyalkyloxyalkyloxy, or lower alkanoyloxy and substituted at the end with radioactive iodine, or alkenyloxymethyl substituted at the end with a radioactive iodine reagent containing the same for assaying central local AchE activity; a method for assaying the central local AchE activity; and labeled precursors of the above compounds. After easily passing through the blood-brain barrier, these compounds are hydrolyzed specifically by AchE in the brain into alcohols, which are then captured by the brain. In contrast, alcohols formed outside the brain do not migrate into the brain. The compounds of the invention emit &ggr;-rays at an appropriate energy level.Type: GrantFiled: January 19, 2001Date of Patent: January 21, 2003Assignees: Daiichi Pure Chemicals Co., Ltd., Daiichi Radioisotope Laboratories, Ltd.Inventors: Toshiaki Irie, Kiyoshi Fukushi, Hiroki Namba, Masaomi Iyo, Nobuo Ikota, Shinichiro Nagatsuka, Takao Ueda, Masaru Nishiura, Keizo Takatoku, Isamu Yomoda
-
Patent number: 6506363Abstract: The present invention concerns the use of a radioiodinated phenolic compound of the formula wherein: m and n are independently 0, 1, 2 or 3, X is a group that is negatively or positively charged at physiological pH, R, R1, R2 and R3 are independently hydrogen, C1-C4 alkyl, or a carboxyl group, and I* is 123I, 131I or 125I, and its pharmaceutically-acceptable salts. The compound is formulated and used in vivo in an animal in brachytherapy in an implantable catheter. In addition, due to the rapid renal clearance of these compounds, they may be used to study renal function. A process to prepare these compounds is also disclosed.Type: GrantFiled: September 28, 2000Date of Patent: January 14, 2003Assignee: The Dow Chemical CompanyInventors: Jaime Simon, R. Keith Frank, Alan D. Strickland
-
Patent number: 6506364Abstract: The present invention concerns the use of a radioiodinated phenolic compound of the formula wherein: m and n are independently 0, 1, 2 or 3, X is a group that is negatively or positively charged at physiological pH, R, R1, R2 and R3 are independently hydrogen, C1-C4 alkyl, or a carboxyl group, and I* is 123I, 131I or 125I, and its pharmaceutically-acceptable salts. The compound is formulated and used in vivo in an animal in brachytherapy in an implantable catheter. In addition, due to the rapid renal clearance of these compounds, they may be used to study renal function. A process to prepare these compounds is also disclosed.Type: GrantFiled: September 28, 2000Date of Patent: January 14, 2003Assignee: The Dow Chemical CompanyInventors: Jaime Simon, Alan D. Strickland, R. Keith Frank
-
Patent number: 6491893Abstract: The present invention provides novel agents for specifically targeting and detecting or treating focal sites of infection or inflammation in a subject.Type: GrantFiled: April 20, 2000Date of Patent: December 10, 2002Assignee: Biostream, Inc.Inventor: John W. Babich
-
Patent number: 6461585Abstract: According to a first aspect of the invention, a process is disclosed for the preparation of radiolabelled haloaromatic compounds. According to a second aspect of the invention, intermediate precursor insoluble polymer compounds used in the preparation of the radiolabelled haloaromatic are disclosed, as well as processes for the preparation of the intermediate precursor insoluble polymer compounds.Type: GrantFiled: July 18, 2000Date of Patent: October 8, 2002Assignee: The University of Western OntarioInventors: Duncan H. Hunter, Xizhen Zhu
-
Patent number: 6447748Abstract: The present invention relates to a class of compounds having affinity for certain cancer cells, e.g. lung carcinomas, colon carcinomas, renal carcinomas, prostate carcinomas, breast carcinomas, malignant melanomas, gliomas, neuroblastomas and pheochromocytomas. The compounds of the present invention can also bind with high specificity to cell surface sigma receptors and can therefore be used for diagnostic imaging of any tissue having an abundance of cells with sigma receptors. The present invention provides such compounds as agents for diagnostic imaging and for detecting and treating tumors containing the cancer cells described above.Type: GrantFiled: August 30, 1999Date of Patent: September 10, 2002Assignee: Research Corporation Technologies, Inc.Inventors: Christy S. John, Jesse Baumgold, John G. McAfee, Terry Moody, Wayne Bowen
-
Patent number: 6447747Abstract: Process for the preparation of radiohalogenated radiopharmaceuticals by an electrophillic substitution, preferably halogenodestannylation reactions, by the reaction of an organometallic substituted precursor, preferably a trialkyl tin substituted precursor, with a radioactive halogen, preferably a radioactive iodine, astatine or bromine composition, in the presence of a catalytically effective amount of an anion selected from the group consisting of bromide, chloride and nitrite anion in an acid medium with an oxidizing agent.Type: GrantFiled: October 28, 1997Date of Patent: September 10, 2002Assignee: Guilford Pharmaceuticals Inc.Inventors: Robert Jean Marie Denis Pirotte, David Peter Nowotnik, Brian Fredrick Abeysekera
-
Publication number: 20020098148Abstract: The present invention relates to a radiolabeled non-steroidal compound having the formula: 1Type: ApplicationFiled: December 15, 1999Publication date: July 25, 2002Inventors: DUANE D. MILLER, LEONID I. KIRKOVSKY, JAMES T. DALTON, ARNAB MUKHERJEE
-
Patent number: 6416735Abstract: Ligands for nAChRs are provided based on various derivatives of methyllycaconitine (MLA) such as radiolabeled MLA, and MLA containing a fluorimetric marker group and their use in imaging for detection of Alzheimer's and other CNS diseases, and combinatorial assays for detection of compounds having affinity for nAChRs, as well as injectable compositions containing the same and kits for performing the imaging studies.Type: GrantFiled: November 8, 1999Date of Patent: July 9, 2002Assignee: Research Triangle InstituteInventors: Frank Ivy Carroll, Hernán A. Navarro, Philip Abraham, Desong Zhong
-
Patent number: 6399042Abstract: A series of compounds in the 4-fluoroalkyl-3-halophenyl nortropanes family are described as diagnostic and therapeutic agents for diseases associated with serotonin transporter dysfunction. These compounds bind to serotonin transporter protein with high affinity and selectivity. The invention provides methods of synthesis which incorporate radioisotopic halogens at a last step which permit high radiochemical yield and maximum usable product life. The radiolabeled compounds of the invention are useful as imaging agents for visualizing the location and density of serotonin transporter by PET and SPECT imaging.Type: GrantFiled: April 26, 2000Date of Patent: June 4, 2002Assignee: Emory UniversityInventors: Mark M. Goodman, Ping Chen
-
Publication number: 20020065429Abstract: The present invention provides improved radioiodinated phospholipid ether analogs which demonstrate significant tumor avidity and longer plasma half-life than shorter-chain analogs. The radioiodinated phospholipid ether analogs of the present invention provide superior imaging and visualization of neoplastic lesions and tumor-specific cytotoxic cancer therapy.Type: ApplicationFiled: July 3, 2001Publication date: May 30, 2002Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Raymond E. Counsell, Marc A. Longino, Anatoly N. Pinchuk, Mark A. Rampy, Jamey P. Weichert